Moleculin Abstract Accepted for Poster Presentation at the Acute Leukemias XIX (ISALXIX) International Symposium
Moleculin Biotech (NASDAQ: MBRX) announced that its abstract has been accepted for poster presentation at the Acute Leukemias XIX (ISALXIX) International Symposium taking place March 16-19, 2025, in Munich, Germany.
The poster presentation (Abstract P002) will focus on 'Liposomal Annamycin in Combination with Cytarabine for Treatment of Acute Myeloid Leukemia (AML)' and will be presented by Dr. Cristina Papayannidis from the University of Bologna's Department of Medical and Surgical Sciences.
Moleculin Biotech (NASDAQ: MBRX) ha annunciato che il suo abstract è stato accettato per una presentazione poster al Simposio Internazionale sulle Leucemie Acute XIX (ISALXIX), che si svolgerà dal 16 al 19 marzo 2025 a Monaco, Germania.
La presentazione poster (Abstract P002) si concentrerà su 'Liposomale Annamycin in combinazione con Citarabina per il trattamento della Leucemia Mieloide Acuta (AML)' e sarà presentata dalla Dr.ssa Cristina Papayannidis del Dipartimento di Scienze Mediche e Chirurgiche dell'Università di Bologna.
Moleculin Biotech (NASDAQ: MBRX) anunció que su resumen ha sido aceptado para una presentación en cartel en el Simposio Internacional sobre Leucemias Agudas XIX (ISALXIX), que se llevará a cabo del 16 al 19 de marzo de 2025 en Múnich, Alemania.
La presentación en cartel (Resumen P002) se centrará en 'Annamycin Liposomal en combinación con Citarabina para el tratamiento de la Leucemia Mieloide Aguda (AML)' y será presentada por la Dra. Cristina Papayannidis del Departamento de Ciencias Médicas y Quirúrgicas de la Universidad de Bolonia.
몰레큘린 바이오텍 (NASDAQ: MBRX)는 그들의 초록이 급성 백혈병 XIX (ISALXIX) 국제 심포지엄에서 포스터 발표로 수락되었다고 발표했습니다. 이 심포지엄은 2025년 3월 16일부터 19일까지 독일 뮌헨에서 열릴 예정입니다.
포스터 발표(초록 P002)는 '급성 골수성 백혈병 (AML) 치료를 위한 리포좀성 안나미신과 시타라빈의 조합'에 초점을 맞추고 있으며, 볼로냐 대학교 의학 및 외과학부의 크리스티나 파파얀니디스 박사가 발표할 예정입니다.
Moleculin Biotech (NASDAQ: MBRX) a annoncé que son résumé a été accepté pour une présentation par affiche lors du Symposium International sur les Leucémies Aiguës XIX (ISALXIX), qui se déroulera du 16 au 19 mars 2025 à Munich, en Allemagne.
La présentation par affiche (Résumé P002) se concentrera sur 'Annamycin Liposomal en combinaison avec Cytarabine pour le traitement de la Leucémie Myéloïde Aiguë (AML)' et sera présentée par Dr. Cristina Papayannidis du Département des Sciences Médicales et Chirurgicales de l'Université de Bologne.
Moleculin Biotech (NASDAQ: MBRX) gab bekannt, dass sein Abstract für eine Posterpräsentation beim Internationalen Symposium über Akute Leukämien XIX (ISALXIX) angenommen wurde, das vom 16. bis 19. März 2025 in München, Deutschland, stattfinden wird.
Die Posterpräsentation (Abstract P002) wird sich auf 'Liposomales Annamycin in Kombination mit Cytarabin zur Behandlung der Akuten Myeloischen Leukämie (AML)' konzentrieren und von Dr. Cristina Papayannidis vom Department für Medizinische und Chirurgische Wissenschaften der Universität Bologna präsentiert.
- Abstract accepted at major international leukemia symposium
- None.
Details for the poster presentation are as follows:
Abstract: P002
Session: Clinical Studies in AML and ALL
Title: Liposomal Annamycin in Combination with Cytarabine for Treatment of Acute Myeloid Leukemia (AML)
Presenting Author: Cristina Papayannidis, MD, PhD, Adjunct professor, Department of Medical and Surgical Sciences, University of Bologna,
For more information about the ISALXIX International Symposium, visit the event website.
About Moleculin Biotech, Inc.
Moleculin Biotech, Inc. is a Phase 3 clinical stage pharmaceutical company advancing a pipeline of therapeutic candidates addressing hard-to-treat tumors and viruses. The Company's lead program, Annamycin, is a next-generation anthracycline designed to avoid multidrug resistance mechanisms and to eliminate the cardiotoxicity common with currently prescribed anthracyclines. Annamycin is currently in development for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma (STS) lung metastases.
The Company is initiating the MIRACLE (Moleculin R/R AML AnnAraC Clinical Evaluation) Trial (MB-108), a pivotal, adaptive design Phase 3 trial evaluating Annamycin in combination with cytarabine, together referred to as AnnAraC, for the treatment of relapsed or refractory acute myeloid leukemia. Following a successful Phase 1B/2 study (MB-106), with input from the FDA, the Company believes it has substantially de-risked the development pathway towards a potential approval for Annamycin for the treatment of AML. This study is subject to appropriate future filings with potential additional feedback from the FDA and their foreign equivalents.
Additionally, the Company is developing WP1066, an Immune/Transcription Modulator capable of inhibiting p-STAT3 and other oncogenic transcription factors while also stimulating a natural immune response, targeting brain tumors, pancreatic and other cancers. Moleculin is also engaged in the development of a portfolio of antimetabolites, including WP1122 for the potential treatment of pathogenic viruses, as well as certain cancer indications.
For more information about the Company, please visit www.moleculin.com and connect on X, LinkedIn and Facebook.
Investor Contact:
JTC Team, LLC
Jenene Thomas
(908) 824-0775
MBRX@jtcir.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/moleculin-abstract-accepted-for-poster-presentation-at-the-acute-leukemias-xix-isalxix-international-symposium-302389270.html
SOURCE Moleculin Biotech, Inc.
FAQ
When and where will Moleculin (MBRX) present its Liposomal Annamycin research?
What is the focus of MBRX's poster presentation at ISALXIX 2025?
Who will present Moleculin's (MBRX) research at the ISALXIX Symposium?
What is the abstract number for MBRX's presentation at ISALXIX 2025?
